Hong Kong innovative drug concept stocks collectively opened lower, BeiGene (06160.HK) opened 3.5% lower, Tiger medicine (03347.HK), Kangfang biological (09926.HK) opened more than 2% lower, Fosun medicine (02196.HK) opened 1.91% lower.
China's central bank: today launched 616 billion yuan 7-day reverse repurchase operation, the bid volume 616 billion yuan, win the bidding volume 616 billion yuan, the operating rate of 1.40%, the same as before.
Hong Kong stocks biomedical concept continued to decline in the afternoon, Tiger medicine (03347.HK) fell more than 6%, Junshi Biosciences (01877.HK), WuXi PharmaTech (02359.HK), Zaiding medicine (09688.HK), BeiGene (06160.HK) and other stocks fell.
Most of the biotechnology stocks in Hong Kong stocks strengthened, Kangsinuo Biological (06185.HK) rose more than 10%, BeiGene (06160.HK) rose more than 6%, Nuocheng Jianhua (09969.HK) rose more than 4%, Tiger Pharmaceutical (03347.HK) rose more than 3%.
港股生物技术股多数走强,康希诺生物(06185.HK)涨超10%,百济神州(06160.HK)涨超6%,诺诚健华(09969.HK)涨超4%,泰格医药(03347.HK)涨超3%。
Hong Kong biomedical plate early strong, Zaiding medicine (09688.HK) rose more than 12%, Junshi Biosciences (01877.HK) rose more than 5%, BeiGene (06160.HK), WuXi PharmaTech (02359.HK) and so on up.
港股生物医药板块盘初走强,再鼎医药(09688.HK)涨超12%,君实生物(01877.HK)涨超5%,百济神州(06160.HK)、药明康德(02359.HK)等跟涨。